These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36608719)

  • 1. Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Chen CH; Wu PH; Lu MC; Ho MW; Hsueh PR
    Int J Antimicrob Agents; 2023 Feb; 61(2):106707. PubMed ID: 36608719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic patterns of Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2019.
    Lee YL; Ko WC; Hsueh PR
    Int J Infect Dis; 2023 Feb; 127():48-55. PubMed ID: 36516915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographical patterns of in vitro susceptibilities to tigecycline and colistin among worldwide isolates of Acinetobacter baumannii, Escherichia coli and Klebsiella pneumoniae: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016-2021.
    Wang JL; Lai CC; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2023 Sep; 62(3):106930. PubMed ID: 37490959
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Han R; Ding L; Yang Y; Guo Y; Yin D; Wu S; Zhi P; Zhu D; Liu Q; Tan X; Zhu Y; Zhang J; Li L; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0147121. PubMed ID: 35138143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014-2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment.
    Hsueh SC; Huang YT; Ko WC; Liu IM; Hsieh PC; Jean SS
    J Glob Antimicrob Resist; 2024 Mar; 36():411-418. PubMed ID: 38331030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018).
    Seifert H; Blondeau J; Lucaßen K; Utt EA
    J Glob Antimicrob Resist; 2022 Dec; 31():82-89. PubMed ID: 35948242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii.
    Seifert H; Stefanik D; Olesky M; Higgins PG
    Int J Antimicrob Agents; 2020 Jan; 55(1):105829. PubMed ID: 31669740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.
    Ni W; Wang Y; Ma X; He Y; Zhao J; Guan J; Li Y; Gao Z
    Eur J Clin Microbiol Infect Dis; 2022 Dec; 41(12):1451-1457. PubMed ID: 36201141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.
    Somily AM; Absar MM; Arshad MZ; Al Aska AI; Shakoor ZA; Fatani AJ; Siddiqui YM; Murray TS
    Saudi Med J; 2012 Jul; 33(7):750-5. PubMed ID: 22821309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline susceptibility of multidrug-resistant Acinetobacter baumannii from intensive care units in the western Balkans.
    Gajic I; Ranin L; Kekic D; Opavski N; Smitran A; Mijac V; Jovanovic S; Hadnadjev M; Travar M; Mijovic G
    Acta Microbiol Immunol Hung; 2020 Mar; 67(3):176-181. PubMed ID: 32160781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.
    Cikman A; Gulhan B; Aydin M; Ceylan MR; Parlak M; Karakecili F; Karagoz A
    Int J Med Sci; 2015; 12(9):695-700. PubMed ID: 26392806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].
    Akin FE; Bayram A; Balci I
    Mikrobiyol Bul; 2010 Apr; 44(2):203-10. PubMed ID: 20549954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update.
    Razavi Nikoo H; Ardebili A; Mardaneh J
    Microb Drug Resist; 2017 Sep; 23(6):744-756. PubMed ID: 28085571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii.
    Wu H; Feng H; He L; Zhang H; Xu P
    Appl Biochem Biotechnol; 2021 Dec; 193(12):3867-3876. PubMed ID: 34524633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Voulgaris GL; Papanikolaou G; Legakis N;
    Int J Antimicrob Agents; 2018 Aug; 52(2):269-271. PubMed ID: 29559273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy.
    Mezzatesta ML; Trovato G; Gona F; Nicolosi VM; Nicolosi D; Carattoli A; Fadda G; Nicoletti G; Stefani S
    Ann Clin Microbiol Antimicrob; 2008 Feb; 7():4. PubMed ID: 18261233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Drug Resistance of
    Gao L; Lyu Y; Li Y
    Chin Med J (Engl); 2017 Mar; 130(6):659-664. PubMed ID: 28303847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
    Ju YG; Lee HJ; Yim HS; Lee MG; Sohn JW; Yoon YK
    Sci Rep; 2022 May; 12(1):7541. PubMed ID: 35534512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.